ATE257152T1 - N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia - Google Patents
N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasiaInfo
- Publication number
- ATE257152T1 ATE257152T1 AT98959050T AT98959050T ATE257152T1 AT E257152 T1 ATE257152 T1 AT E257152T1 AT 98959050 T AT98959050 T AT 98959050T AT 98959050 T AT98959050 T AT 98959050T AT E257152 T1 ATE257152 T1 AT E257152T1
- Authority
- AT
- Austria
- Prior art keywords
- benzyl
- treatment
- indenylaceamide
- neoplasia
- derivative
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000007859 condensation product Substances 0.000 abstract 1
- -1 heterocyclic aldehydes Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- NNPSGLWEKFBPKR-UHFFFAOYSA-N n-benzyl-2-(3h-inden-1-yl)acetamide Chemical class C=1CC2=CC=CC=C2C=1CC(=O)NCC1=CC=CC=C1 NNPSGLWEKFBPKR-UHFFFAOYSA-N 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,353 US5948779A (en) | 1997-12-12 | 1997-12-12 | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
| US09/206,245 US6066634A (en) | 1997-12-12 | 1998-12-07 | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia |
| PCT/GB1998/003712 WO1999031065A1 (en) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylacetamides derivatives for treating neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257152T1 true ATE257152T1 (de) | 2004-01-15 |
Family
ID=26901185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98959050T ATE257152T1 (de) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6166053A (de) |
| EP (1) | EP1044187B1 (de) |
| JP (1) | JP4307719B2 (de) |
| CN (1) | CN100436418C (de) |
| AT (1) | ATE257152T1 (de) |
| AU (1) | AU752072B2 (de) |
| BR (1) | BR9813540A (de) |
| CA (1) | CA2314339C (de) |
| CZ (1) | CZ298826B6 (de) |
| DE (1) | DE69820908T2 (de) |
| ES (1) | ES2212383T3 (de) |
| HU (1) | HU227153B1 (de) |
| IL (1) | IL136603A0 (de) |
| NO (1) | NO317097B1 (de) |
| NZ (1) | NZ504958A (de) |
| PL (1) | PL196936B1 (de) |
| TR (1) | TR200001687T2 (de) |
| WO (1) | WO1999031065A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314339C (en) * | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
| IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
| CN1436080A (zh) | 2000-04-19 | 2003-08-13 | 利利艾科斯有限公司 | 环gmp-特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途 |
| DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| WO2002067936A1 (en) * | 2001-02-21 | 2002-09-06 | Cell Pathways, Inc. | Methods for treatment of inflammatory bowel disease |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
| US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| US20030073740A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of lupus erythematosus |
| CN100398522C (zh) * | 2003-08-20 | 2008-07-02 | Irm责任有限公司 | 组织蛋白酶s的抑制剂 |
| US6995622B2 (en) * | 2004-01-09 | 2006-02-07 | Robert Bosh Gmbh | Frequency and/or phase compensated microelectromechanical oscillator |
| JP2008501407A (ja) | 2004-06-02 | 2008-01-24 | メリット ダイアモンド コーポレイション | 装身具のための快適な内側およびその内側を備える装身具 |
| CN1332930C (zh) * | 2005-08-05 | 2007-08-22 | 中国科学院上海有机化学研究所 | 制备乙氰菊酯前体的方法 |
| EP1968616A4 (de) * | 2006-01-04 | 2009-10-21 | Southern Res Inst | Sulindac-derivate, ihre verwendung und herstellung |
| WO2009022756A1 (ja) * | 2007-08-13 | 2009-02-19 | Katayama Chemical Industries Co., Ltd. | 虚血性疾患の診断及び治療 |
| EP2365746B1 (de) * | 2008-11-04 | 2014-07-16 | Wellstat Therapeutics Corporation | Synthese von (phenylalkyloxy)phenyloxobutansäuren |
| KR20120061085A (ko) | 2009-08-07 | 2012-06-12 | 오클랜드 유니서비시즈 리미티드 | 도로에서 전력을 공급받는 전기 차량 시스템 |
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| US11186596B2 (en) | 2018-04-26 | 2021-11-30 | Adt Pharmaceuticals, Llc | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0508586B1 (de) * | 1991-03-08 | 1995-05-31 | Fgn, Inc. | Substituierte Indenylverbindungen |
| US6063818A (en) * | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
| CA2314339C (en) * | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
| US5948779A (en) * | 1997-12-12 | 1999-09-07 | Cell Pathways, Inc. | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
-
1998
- 1998-12-11 CA CA002314339A patent/CA2314339C/en not_active Expired - Fee Related
- 1998-12-11 EP EP98959050A patent/EP1044187B1/de not_active Expired - Lifetime
- 1998-12-11 AT AT98959050T patent/ATE257152T1/de not_active IP Right Cessation
- 1998-12-11 DE DE69820908T patent/DE69820908T2/de not_active Expired - Lifetime
- 1998-12-11 TR TR2000/01687T patent/TR200001687T2/xx unknown
- 1998-12-11 JP JP2000538992A patent/JP4307719B2/ja not_active Expired - Fee Related
- 1998-12-11 IL IL13660398A patent/IL136603A0/xx active IP Right Grant
- 1998-12-11 NZ NZ504958A patent/NZ504958A/xx unknown
- 1998-12-11 PL PL341151A patent/PL196936B1/pl not_active IP Right Cessation
- 1998-12-11 WO PCT/GB1998/003712 patent/WO1999031065A1/en not_active Ceased
- 1998-12-11 BR BR9813540-6A patent/BR9813540A/pt not_active Application Discontinuation
- 1998-12-11 CZ CZ20002157A patent/CZ298826B6/cs not_active IP Right Cessation
- 1998-12-11 CN CNB988118955A patent/CN100436418C/zh not_active Expired - Fee Related
- 1998-12-11 HU HU0100170A patent/HU227153B1/hu not_active IP Right Cessation
- 1998-12-11 ES ES98959050T patent/ES2212383T3/es not_active Expired - Lifetime
- 1998-12-11 AU AU14981/99A patent/AU752072B2/en not_active Ceased
-
2000
- 2000-01-24 US US09/490,269 patent/US6166053A/en not_active Expired - Lifetime
- 2000-06-09 NO NO20002972A patent/NO317097B1/no not_active IP Right Cessation
- 2000-12-20 US US09/741,970 patent/US6426349B1/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/206,687 patent/US6610854B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1044187B1 (de) | 2004-01-02 |
| DE69820908T2 (de) | 2004-12-23 |
| ES2212383T3 (es) | 2004-07-16 |
| HUP0100170A1 (hu) | 2001-07-30 |
| EP1044187A1 (de) | 2000-10-18 |
| CA2314339C (en) | 2009-09-08 |
| IL136603A0 (en) | 2001-06-14 |
| NO20002972L (no) | 2000-08-09 |
| CA2314339A1 (en) | 1999-06-24 |
| JP2002508358A (ja) | 2002-03-19 |
| PL196936B1 (pl) | 2008-02-29 |
| HUP0100170A3 (en) | 2001-12-28 |
| NO20002972D0 (no) | 2000-06-09 |
| TR200001687T2 (tr) | 2000-10-23 |
| US6166053A (en) | 2000-12-26 |
| CZ298826B6 (cs) | 2008-02-20 |
| US20030009033A1 (en) | 2003-01-09 |
| CN100436418C (zh) | 2008-11-26 |
| WO1999031065A1 (en) | 1999-06-24 |
| CZ20002157A3 (cs) | 2000-10-11 |
| BR9813540A (pt) | 2000-10-10 |
| CN1281436A (zh) | 2001-01-24 |
| JP4307719B2 (ja) | 2009-08-05 |
| PL341151A1 (en) | 2001-03-26 |
| NZ504958A (en) | 2003-03-28 |
| US6426349B1 (en) | 2002-07-30 |
| AU752072B2 (en) | 2002-09-05 |
| AU1498199A (en) | 1999-07-05 |
| US6610854B2 (en) | 2003-08-26 |
| HU227153B1 (en) | 2010-08-30 |
| NO317097B1 (no) | 2004-08-09 |
| DE69820908D1 (de) | 2004-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69820908D1 (de) | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia | |
| SG144712A1 (en) | Nordihydroguaiartic derivaties for use in treatment of tumors | |
| DK0960127T3 (da) | Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf | |
| ATE222769T1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| ES2167401T3 (es) | Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias. | |
| ATE239509T1 (de) | Konjugate zur behandlung von prostatakrebs | |
| ATE375795T1 (de) | Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs | |
| DE69921981D1 (de) | ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS | |
| WO2000055629A3 (en) | Methods of diagnosing and treating breast cancer | |
| AR016981A2 (es) | Polipeptidos sinteticos | |
| DE69940980D1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
| DE69927688D1 (de) | Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs | |
| EP0910380A4 (de) | Substituierte benzyliden-indenyl-formamide, acetamide und propionamide | |
| ATE233483T1 (de) | Wässrige lösung zum konservieren von gewebe und organen | |
| BR9907025B1 (pt) | Polissacarídeos sintéticos e uso dos mesmos | |
| ATE362765T1 (de) | Milchsäurebakterien mit anxiolytischer wirkung, und ihre verwendungen | |
| PT971710E (pt) | Utilizacao de queleritrina e radiacao para terapia de tumores | |
| DE60026046D1 (de) | 5-hydroxysapogenin derivate mit aktivität gegen demenz | |
| DE69732246D1 (de) | Gewebespezifische expression des retinoblastoma-proteins | |
| ATE417926T1 (de) | Zusammensetzungen zur modulierung der länge von telomeren | |
| DE69901805D1 (de) | Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin | |
| FI871545A7 (fi) | Menetelmä syövän hoitoon käytettävän synergistisen seoksen valmistamiseksi, joka sisältää interleukiini-2:ta ja/tai interferoni- :aa ja kasvainnekroositekijää. | |
| ATE233093T1 (de) | Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren | |
| AU1128801A (en) | Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |